Release Date: 23-Jan-2025
SI B001 is a bispecific antibody under development by Sichuan Baili Pharmaceutical (Biokin Pharmaceutical) in China and its subsidiary SystImmune in the United States. It is being investigated for the treatment of solid tumors, particularly those that express the epidermal growth factor receptor (EGFR) and HER3 (also known as ErbB3). These receptors are critical to the signaling pathways that drive the proliferation and survival of cancer cells, making them important therapeutic targets. SI B001 is designed to inhibit the EGFR/HER3 signaling pathway, which is known to be closely linked to tumor cell growth.
Download Report: https://www.kuickresearch.com/ccformF.php?t=1737625307
The mechanism of action of SI B001 involves its ability to simultaneously bind to both EGFR and HER3 receptors on cancer cells. By binding to these two receptors, SI B001 prevents their phosphorylation and activation, thus blocking the downstream signaling that would typically lead to cancer cell proliferation. This dual inhibition is intended to disrupt the growth signals that cancer cells rely on for survival, making SI B001 an effective strategy for targeting tumors with aberrant EGFR and HER3 expression.
Developed using SystImmune’s Specificity Enhanced Bi-specific Antibody (SEBA) platform, SI B001 leverages a unique tetravalent structure with two binding domains. This allows the antibody to specifically target and block the EGFR/HER3 signaling pathway while also harnessing the potential of the immune system. The SEBA technology enables SI B001 to bind to one surface protein for precise targeting of cancer cells, while simultaneously blocking a second protein, which may not be specific to the cancer but still contributes to therapeutic efficacy. This enhanced specificity and dual mechanism of action provide SI B001 with significant potential in treating a wide range of solid tumors.
Currently, SI B001 is undergoing Phase 3 clinical trials for several cancer types, including non-small cell lung adenocarcinoma, squamous cell carcinoma of the lung, colorectal cancer, and head and neck squamous cell carcinoma. These trials aim to evaluate the safety and efficacy of SI B001 as a single-agent therapy for patients with various solid tumor indications.